BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Stem Cell News » Press Releases » Page 6

Exogenus Therapeutics and Boehringer Ingelheim Collaboratively Explore Extracellular Vesicles for Regenerative Medicine Applications

March 6, 2022 By Cade Hildreth (CEO) Leave a Comment

Exogenus Therapeutics and Boehringer Ingelheim

Cantanhede, Portugal, March 2, 2022 – Exogenus Therapeutics is proud to announce a new research collaboration with Boehringer Ingelheim to explore the use of extracellular vesicles as therapeutic tools for regenerative medicine. This joint effort led by Boehringer Ingelheim’s Research Beyond Borders (RBB) Unit focuses on pre-clinical testing of Exogenus Therapeutics’ lead candidate Exo-101, in various regenerative medicine indications. [Read more…]

Filed Under: Exosomes, Press Releases

Legend Biotech’s CARVYKTI™ Becomes Latest CAR-T Therapy Approved by U.S. FDA

March 3, 2022 By Cade Hildreth (CEO) Leave a Comment

Legend Biotech CAR-T Therapy
  • CARVYKTI™ (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, Receives U.S. FDA Approval for the Treatment of Adult Patients With Relapsed or Refractory Multiple Myeloma
  • CARVYKTI™ marks the first product approved by a health authority for Legend Biotech
  • Approval is primarily based on the pivotal phase 1b/2 CARTITUDE-1 study, which demonstrated an overall response rate (ORR) of 98 percent in patients with refractory or relapsed multiple myeloma after four or more prior lines of therapy including proteasome inhibitor, immunomodulatory agent and anti-CD38 monoclonal antibody1

[Read more…]

Filed Under: CAR-T, Cell Therapy, Press Releases

Treefrog Therapeutics appoints Scientific Advisory Board to guide the development of proprietary iPS platform & cell therapy pipeline

March 1, 2022 By Cade Hildreth (CEO) Leave a Comment

Treefrog Scientific Advisory Board

Bordeaux, France / March 1st, 2022 – TreeFrog Therapeutics, a French-based biotech aimed at making safer, more efficient and more affordable off-the-shelf cell therapies based on induced pluripotent stem cells (iPSCs), today announces the formation of its Scientific Advisory Board (SAB). Bringing together world-class experts in biophysics, pluripotent stem cell biology and gene editing, the newly created SAB will guide the development of proprietary C-StemTM technology platform and in-house cell therapy programs. [Read more…]

Filed Under: iPS Cells, Press Releases, Stem Cell News

FDA Grants Orphan Drug Designation to Celularity’s CYNK-101, an NK Cell Therapy for GI Cancers

February 23, 2022 By Cade Hildreth (CEO) Leave a Comment

Celularity CYNK-101
CYNK-101 is an investigational genetically modified NK cell therapy designed to synergize with antibody therapeutics for difficult to treat cancers of high unmet medical need
Phase 1/2a clinical trial will evaluate the safety and preliminary efficacy of CYNK-101 in combination with standard chemotherapy, trastuzumab, and pembrolizumab
5th designation received by Celularity within 12 months from the US FDA

[Read more…]

Filed Under: Cell Therapy, Press Releases, Stem Cell News

GIOSTAR Chicago Explores Holistic Healing with Chopra Global Chief Medical Officer

February 22, 2022 By Cade Hildreth (CEO) Leave a Comment

GIOTAR Chopra
Company continues analysis of innovative approaches to healthcare with pioneer in the space

CHICAGO, Feb. 22, 2022 — GIOSTAR Chicago – a leader in regenerative technologies – recently conducted a discussion on holistic healing with Dr. Sheila Patel. The conversation was led by Shelly Sood, GIOSTAR Chicago Founding Partner. Dr. Patel is a board-certified family physician and Chief Medical Officer (CMO) of Chopra Global – “a modern healthcare company positioned at the intersection of science and spirituality,” founded by renowned healthcare expert Dr. Deepak Chopra. The full interview is available on the GIOSTAR Chicago Website, with an accompanying transcript. [Read more…]

Filed Under: Cell Therapy, Press Releases, Stem Cell News

  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 66
  • Next Page »

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Top Rated Products

  • Job Posting on BioInformant <Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience $297
  • U.S. Cord Blood Banking Survey <Cord Blood Banking Survey of U.S. Parents [2017] $197
  • Exosome Companies 2020 <Global Database of Exosome Companies $149 $97

Featured Posts

what are exosomes | definition

What are Exosomes, Exactly?

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

iPSC derived cell therapeutics

The Pipeline for iPSC-Derived Cell Therapeutics in 2022

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.